Abstract:Immune checkpoints are a group of immune regulatory plasma membrane proteins expressed on antigen-presenting cells and T cells, which are crucial for maintaining self-immune tolerance and modulating the effectiveness of T cell immune responses. The importance of selected immune checkpoints in cardiovascular diseases have been widely recognized. However, we identified a significant knowledge gap in the comprehensive understanding of immune checkpoint signaling across multiple levels in cardiovascular diseases. To bridge this gap, we developed a framework that encompasses disease stages and cell types regulated by immune checkpoint axes within the contexts of three major aortic diseases such as abdominal aortic aneurysm, atherosclerosis, and diabetic aortic pathology. Initially, at the transcriptional level, we analyzed the expressions of 58 pairs of immune checkpoint genes in mouse aorta across three models of abdominal aortic aneurysm, four models of hyperlipidemia and atherosclerosis, and three models of diabetes, each representing various stages of the respective diseases. At the single-cell level, we investigated the gene enrichment within separate clusters of aortic cells under diseased conditions. From the results, we found that among the immunosuppressive or double functional immune checkpoints, CD155 expression patterns were different from that of CD274 in more than 50% samples, suggesting that CD155 may play immunosuppressive/anti-inflammatory roles in aortic diseases that are different from CD274. Therefore, we performed flow cytometry to investigate potential regulation of the TIGIT/CD155 axis at the cellular levels in four organs of ApoE-/- mice compared to wild type. The results identified that TIGIT/CD155 axis is upregulated in aortic CD45+ leukocytes but not in CD45- non-leukocyte cellular compartments. CD155 enrichments were identified in CD45+CD11b+CD11c+ cells in blood and kidney, as well as in CD45+CD11b-CD11c+ cells in the lung. Furthermore, among the three functional markers used to identify the subclusters of heterogeneous aortic antigen-presenting cells—CD206, CX3CR1, and CD103—positive correlations were observed between CD155 expressions and the anti-inflammatory marker CD206, while correlations with CX3CR1 and CD103 were absent. These results have demonstrated that CD155-CD206 pathway may play surrogative roles to CD274 in suppressing inflammation and immune responses in atherosclerosis and aortic diseases.

Abstract 20762: IL-35, a Newly Proposed Homeostasis-Associated Molecular Pattern, Suppresses Aortic Endothelial Cell Activation and Atherosclerosis by Inhibiting Mitochondrial ROS-Mediated Site-Specific Acetylation of H3K14

Abstract 029: Interleukin-35 Suppresses Endothelial Activation by Inhibiting Mitochondrial Reactive Oxygen Species Mediated Site-specific Acetylation of Histone 3 Lysine 14

Abstract 211: IL-35 Suppresses Endothelial Cell Activation by Inhibiting Histone H3K14 Acetylation and AP-1

IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (histone 3 Lysine 14).

IL-35, As a Newly Proposed Homeostasis-Associated Molecular Pattern, Plays Three Major Functions Including Anti-Inflammatory Initiator, Effector, and Blocker in Cardiovascular Diseases

Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells.

IL-35 promotes CD4<SUP>+</SUP>Foxp3<SUP>+</SUP> Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms

Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing Mapk-Ap-1 Pathway

IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms

Abstract 13985: Anti-inflammatory Cytokine Interleukin-35 Inhibits Lipopolysaccharide-induced Vascular Inflammation

IL-35 Suppresses Lipopolysaccharide-Induced Endothelial Cell Activation Through Downregulation of MAPK Signaling-Mediated Upregulation of Adhesion Molecule VCAM-1

The Modulation of Endoplasmic Reticulum Stress by Chemical Chaperone Upregulates Immune Negative Cytokine IL-35 in Apolipoprotein E-Deficient Mice

Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis

Abstract 4146493: 84 Immune Checkpoint Profiling in Major Aortic Diseases Leads to Identification of Potential Roles of CD155-CD206 Pathway in Suppressing Inflammation and Immune Responses

IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis.

Abstract 710: Hyperlipidemia Induces a Novel Tissue Compartmentation Change of CD4+Foxp3+ Regulatory T Cells, Which Weakens Regulatory T Cells Suppression of Atherogenic Iimmune Responses in Aorta

Abstract 16746: Novel Role of Endothelial CD45 in Regulating Endothelial-to-Mesenchymal Transition (endmt) in Atherosclerosis

Interleukin-12p35 Deficiency Reverses the Th1/Th2 Imbalance, Aggravates the Th17/Treg Imbalance, and Ameliorates Atherosclerosis in ApoE-/- Mice

Interleukin-35 ameliorates cardiovascular disease by suppressing inflammatory responses and regulating immune homeostasis

IL‐35 Ameliorates Collagen‐induced Arthritis by Promoting TNF‐α‐induced Apoptosis of Synovial Fibroblasts and Stimulating M2 Macrophages Polarization

Interleukin-17A Promotes Aortic Endothelial Cell Activation Via Transcriptionally and Post-translationally Activating P38 Mitogen-activated Protein Kinase (MAPK) Pathway.